Staff Profile
Philip Berry
Senior Scientific Officer/Trials Analyst
- Email: philip.berry@ncl.ac.uk
- Address: Northern Institute for Cancer Research,
Newcastle University,
Framlington Place,
NE2 4HH,
England
Background
I work within the clinical and translational research group where I manage the NICR Chromatography lab which comprises of HPLC and LC-MS equipment.
My work is primarily focussed towards pharmacokinetic research . I also spend time looking at improvements to our analytical techniques in order to get data from more complex samples, with greater sensitivity and efficiency.
Research
Research areas I'm interested in include:
Small volume / high sensitivity sampling techniques,
Biotherapeutic monitoring
All forms of mass spectrometry
Novel chromatography techniques
Pharmacokinetic drug monitoring
Publications
- Stewart CH, Berry P, Przulj D, Treanor C. Cancer-related health behaviours of young people not in education, employment or training ('NEET'): a cross-sectional study. BMC Cancer 2018, 17, 165.
- Coulthard SA, McGarrity S, Sahota K, Berry P, Redfern CPF. Three Faces of Mercaptopurine Cytotoxicity in vitro: Methylation, Nucleotide Homeostasis and Deoxythioguanosine in DNA. Drug Metabolism and Disposition 2018, 46(8), 1191-1199.
- Coulthard SA, Berry P, McGarrity S, McLaughlin S, Ansari A, Redfern CPF. Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone. Inflammatory Bowel Diseases 2017, 23(6), 946-955.
- Zangarini M, Berry P, Sludden J, Raynaud FI, Banerji U, Jones P, Edwards D, Veal GJ. Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma. Bioanalysis 2017, 9(13), 1001-1010.
- Zangarini M, Rajan N, Danilenko M, Berry P, Traversa S, Veal GJ. Development and validation of LC–MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors. Bioanalysis 2017, 9(3), 279-288.
- Chen L, Pastorino F, Berry P, Bonner J, Wood K, Veal G, Ponzoni M, Lunec J, Newell DR, Tweddle DA. In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma. In: AACR Annual Meeting 2017. 2017, Washington, DC: American Association for Cancer Research.
- Veal GJ, Malik S, Lupo M, MacFarlane S, Lepola P, Costello M, Ceci A, Boué C, Lecour L, Otto A, Rastegari M, Berry P. Investigating the roles and training of paediatric research nurses working across Europe: a questionnaire-based survey. BMJ Paediatrics Open 2017, 1(1), 1-7.
- Coulthard S, Berry P, McGarrity S, Redfern C. A Novel Assay for The Direct Detection of Deoxythioguanosine (DTG) in DNA from Patients On Azathioprine Using Liquid Chromatography and Tandem Mass Spectrometry (LC-MS/MS). In: Annual General Meeting of the British Society of Gastroenterology. 2016, Liverpool: BMJ Publishing Group.
- Coulthard S, Berry P, McGarrity S, Kobayashi T, Toyonaga T, Ansari A, Redfern C. Deoxythioguanosine (DTG) in DNA as a Pharmacological Endpoint of Thiopurine Treatment in Inflammatory Bowel Disease Patients. In: British Society of Gastroenterology Annual General Meeting. 2016, Liverpool: BMJ Publishing Group.
- Coulthard SA, Berry P, McGarrity S, Ansari A, Redfern CPF. Liquid chromatography-mass spectrometry for measuring deoxythioguanosine in DNA from thiopurine-treated patients. Journal of Chromatography B 2016, 1028, 175-180.
- Coulthard SA, Berry P, McGarrity S, Ansari A, Redfern CPF. Liquid chromatography-mass spectrometry for measuring deoxythioguanosine in DNA from thiopurine-treated patients. Journal of Chromatography B 2016, 1028, 175-180.
- Lietz G, Oxley A, Berry P, Hesketh J, Tourniaire F, Park H, Green M, Boddy A. β-carotene (BC) bioconversion is similar in men and women. The FASEB Journal 2015, 29(Suppl. 1).
- Oxley A, Berry P, Taylor GA, Cowell J, Hall MJ, Hesketh J, Lietz G, Boddy AV. An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion and vitamin A status in humans. Journal of Lipid Research 2014, 55(2), 319-328.
- Mould E, Berry P, Jamieson D, Hill C, Cano C, Tan N, Elliott S, Durkacz B, Newell D, Willmore E. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity. Biochemical Pharmacology 2014, 88(1), 58-65.
- Park H, Lietz G, Oxley A, Boddy A, Berry P, Wyss A, Schalch W, Green M. Simplified approaches for estimating vitamin A stores and β-carotene bioconversion in humans. The FASEB Journal 2014, 28(Suppl. 1), 39.6.
- Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, Nichols GL, Del Bello F, Piergentili A, Newell DR, Lunec J, Tweddle DA. Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma. British Journal of Cancer 2014, 111, 716-725.
- Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer 2014, 110, 1977-1984.
- Oxley A, Berry P, Hall MJ, Cowell J, Hesketh J, Lietz G, Boddy AV. An LC-MS/MS Method for Stable Isotope Dilution Studies of β-Carotene Bioavailability, Bioconversion and Vitamin A Status in Humans. In: European Journal of Ophthalmology. 2013, Cambridge, UK: Wichtig Publishing.
- Oxley A, Berry P, Cowell J, Hall M, Hesketh J, Lietz G, Boddy AV. An LC-MS/MS method for stable isotope dilution studies of β-carotene bioefficacy and vitamin A status in humans. In: Nutrition Society Annual Summer Meeting. 2013, Newcastle upon Tyne, UK: Cambridge University Press.
- Oxley A, Berry P, Hesketh J, Boddy AV, Lietz G. Gender differences in retinol metabolism are independent of β-carotene bioconversion. In: Nutrition Society Annual Summer Meeting. 2013, Newcastle upon Tyne, UK: Cambridge University Press.
- Mould E, Berry P, Jamieson D, Hill C, Tan N, Elliott S, Durkacz B, Newell D, Willmore E. The DNA-PK inhibitor, NU7441, sensitises cancer cells to microtubule-targeting agents and modulates vincristine efflux in multidrug resistant cells. In: American Association for Cancer Research 104th Annual Meeting. 2013, Washington, DC, USA: American Association for Cancer Research.